Generalized myasthenia gravis is an autoimmune disorder in which antibodies against acetylcholine receptors block signals transmitted from nerves to muscles. It causes muscle weakness that can affect the respiratory system and be debilitating. Localized or general muscle weakness is the predominant symptom and is induced by the antibodies. It is diagnosed as pt can't open eye or mouth after a few morning hrs.
A randomized, double-blind phase 2 trial show zilucoplan to be safe and effective in treating patients with generalized myasthenia gravis (gMG). Long-term data from the open-label extension phase of the study, presented at the American Academy of Neurology (AAN) 2019 Annual Meeting showed significantly sustained responses at 24 weeks for subjects receiving the study drug at 0.3 mg/kg daily. In a group of 44 patients, daily 0.3 mg/kg of zilucoplan significantly reduced Quantitative…
